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The promise and predicament of cosmetic neurology
Abstract
Advances in cognitive neuroscience make cosmetic neurology in some form inevitable and will give rise
to extremely difficult ethical issues.
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Consider the following hypothetical case study. A well heeled executive walks into my
cognitive neurology clinic because he is concerned that he is becoming forgetful. It turns
out that he is going through a difficult divorce and my clinical impression is that his
memory problems stem from the stress he is experiencing. I place him on a selective
seratonin reuptake inhibitor, sertraline, and in a few weeks he feels better. Around this
time his 13 year old daughter has difficulty at school and is diagnosed by the school
psychologist as having attention deficit disorder. I place her on adderall, a stimulant
combination drug, which seems to help with her behaviour in school. My patient then
comes to me because he is experiencing the "tip of the tongue" phenomena more
frequently. He is concerned that his word finding difficulty interferes with his ability to
function in high level meetings. I suggest we try a cholinesterase inhibitor to see if this
helps. I am careful to explain that the Food and Drug Administration does not approve
such a use for this medication. He wants to try it and is pleased with the results.
A few months later, this patient visits me with his 16 year old son, a talented middle
distance runner. His father thinks if he were just a bit better, among the elite high school
runners in the state, he would be far more competitive as an applicant for selective
colleges. We discuss various options. Because of a recent report that sildenafil, which is
used conventionally for male impotence, may improve oxygen carrying capacity, I
prescribe this medication. The son does not object.
Encouraged by these pharmacologic successes, my patient approaches me with an
interesting problem. He is planning a trip to Saudi Arabia in a couple of months to bid for
a lucrative contract. He thinks that learning Arabic would give him a decided edge over
his competitors and is enrolling in an intensive crash course to learn the language. He
wants to know if I can help. Because of data suggesting that amphetamines promote
neural plasticity and improve recovery in aphasic patients, I advise him to take a small
dose of dextro-amphetamine half an hour before each of his classes.

When he is ready to fly to Saudi Arabia I give him my recently patented "travel pack"—a
hypnotic, zolpidem, to be taken when he gets on the plane and a stimulant, modafanil, to
be taken when he gets off the plane. He goes to Saudi Arabia, impresses the royal family
with his Arabic, and wins the contract. Triumphant, he makes a large donation to my
research programme. And we all live happily ever after.
Or do we? If such a scenario is plausible, is it desirable or is it dystopic? In what follows,
I review what is plausible in the practice of pharmacological enhancements and the kinds
of ethical issues that would surface from such a practice. While the hypothetical case
described may seem extreme now, it might not in the future.

THE PROMISE
What can be done in cosmetic neurology and what is likely to be possible in the near
future? This topic has received some attention in the lay press1–6 and in the scientific
literature,7,8,9,10 but relatively little in clinical circles.11 The possibilities for enhancement
fall into three broad categories: motor abilities, cognition, and affective systems.
The targets for enhancement of motor abilities encompass cardiovascular, peripheral
motor, and central nervous systems. For cardiovascular systems, human erythropoietin is
used to increase oxygen carrying capacities for better endurance.12 New transfusion
methods are likely to be used in this way, and, as mentioned already, sildenafil may have
similar effects.13 To enhance motor systems, athletes use anabolic steroids commonly, an
issue that has preoccupied even those at the highest level of American politics.14 Insulin
like growth factor may increase muscle mass and prevent muscular decline associated
with ageing.15,16 Musicians frequently use beta blockers to dampen physiological tremors
in order to improve their performances.17 Finally, targeting the central nervous system,
dopamine agonists may improve the acquisition of motor skills. Such agonists are
associated with greater neural plasticity, and the use of dextro-amphetamine, when paired
with physical therapy, appears to hasten motor learning following stroke.18,19
Intense research efforts in the last few decades are yielding novel treatments for cognitive
disorders such as Alzheimer’s disease and attention deficit disorder. These medications
are also likely to modulate attention, memory, and learning in healthy individuals.
Cholinesterase inhibitors may improve normal performance under some circumstances.20
Modafinil can be used to improve vigilance and reduce impulsive responding,21
especially in sleep deprived states, and it is being studied extensively by the armed
services.22 New non-addictive stimulant medications, such as atomoxetine, are also likely
to improve levels of arousal in normal subjects. Based on the belief that these drugs
improve test performance, the use of stimulant medications among college students in the
US is widespread.23 Interestingly, the effects of these medications may be influenced by
genetic endowments such as which catechol O-methyltransferase alleles are inherited.24
This observation raises the possibility that enhancement cocktails might eventually be
tailored to individual genetic profiles.

Particularly intriguing are the development of new classes of drugs, such as ampakines
and cyclic AMP response element binding protein (CREB) modulators. They are striking,
because they are not being developed with a disease in mind. These medications promote
the intracellular cascade of events leading up to the structural neural changes associated
with the acquisition of long term memories.25–28 Most of the drugs discussed in this paper
are developed to treat disorders. As an afterthought, they may also enhance normal
abilities. By contrast, ampakines and CREB modulators are developed to augment normal
encoding mechanisms. They might then also apply to disease states.
Finally, we continue to refine ways to modify affective systems. Such developments are
desirable given that some estimate that up to one in five Americans are depressed,29 and
recent surveys suggest that close to half of adult Americans suffer from affective and
substance abuse illnesses.30 Given that affective illnesses often lie on continua, more
people than those who meet checklist criteria might actually benefit from these
medications. Beta blockers, sometimes used for anxiety, appear to help with posttraumatic symptoms in individuals who come to emergency departments after car
crashes.31 Serotonin reuptake inhibitors are used widely and seem to promote affiliative
behaviour in healthy states.32,33 Around the corner are a host of potentially new ways of
controlling affective states with the modulation of neuropeptides34 such as substance P,
vasopressin, galanin, and neuropeptide Y. Corticotropin release factor (CRF) seems to
mediate the long term effects of stress,35,36 and blocking CRF may blunt these effects.37
The subtlety with which affective states might be modulated in the future is hard to
predict. However, heralding the way in which emotional states might be "fine tuned", a
recent study found that inhaling oxytocin promotes feelings of trust, and that these
feelings affect behaviour.38
The general point that I would like to highlight is the following. The armamentarium of
drugs that could be used to enhance healthy individuals is growing. We can expect that
this growth will continue for the indefinite future. Medications for impotence, hair loss,
and obesity are sometimes referred to as "lifestyle" drugs.39 The medications under
consideration here seem to have more pervasive effects—where the altering of substance
rather than style is what is at issue. We can expect that drugs will be targeted for specific
effects and that they will be targeted for specific genetic profiles.

THE PREDICAMENT
Four reasons might give pause to the practice of cosmetic neurology. These concerns
have to do with safety, character, justice, and autonomy.
Safety concerns are familiar. Most medications can have unpleasant side effects. Are the
risks of these effects worth the expected benefits? The use of drugs in various
combinations could complicate the safety concern in unpredictable ways. Physiological
and psychological addictions might occur. Since most clinical trials are designed to test
safety over relatively short periods, potential long term toxicities are not known when
drugs are introduced into the market. In disease states, one weighs the potential benefits
versus the potential risks in making decisions. Thus, one might tolerate significant risk

when the alternative is a relentlessly progressive disease like Jacob Creutzfeldt disease.
Are any risks tolerable when the alternative is normality?
In my view, safety is more of a pragmatic than an ethical concern. The nature of drug
development is that some problematic effects will occur that could not be predicted.
However, all the parties involved—patient/consumers, physicians, and pharmaceutical
companies—are interested in having drugs that are safe. Since there are no inherent
conflicts of interest, and as long as information about side effects is not suppressed, the
ethical issues do not cut deeply.
The character concern has to do with undermining our sense of identity and what gives
meaning to our lives.40 The concern is often placed in a "no pain, no gain" framework.
Struggling in some situations and experiencing distress and failure are quintessential
aspects of human experience. Enhancing cognition is somehow cheating. Side stepping
distress is somehow cheapening. These experiences give rise to desirable personal
attributes. Recent studies find that observing someone in pain activates the same neural
circuits that are involved when one experiences pain.41,42 One infers from such studies
that some painful experiences are probably necessary in developing empathy.
The character concern is hard to dispense with. While this remains a deep concern, it is
hard to see how this concern would precipitate into public policy or even into consistent
social norms. Who decides which pains should be suffered to build character and which
can be reasonably avoided? The meaning given to pain that women might experience in
childbirth has varied in different settings, from atonement for original sin to promotion of
mother infant bonds.43 Pain and suffering more generally can take on spiritual
significance.44 Yet many would not accept mandates that prohibit the amelioration of
specific pains. In cultures with strong libertarian tendencies it is hard to see how
individuals will not insist on making decisions about what to do with their own bodies
and brains, for better and for worse.
The justice concern is about equitable distribution of resources. Medications used for
enhancements are unlikely to be paid for by insurance companies or by socialised
healthcare systems. That means the wealthy will avail themselves of designer drugs,
whereas the poor will be confined to coffee, booze, and cigarettes. On the assumption that
the enhancement drugs work to improve abilities, unequal access to them will widen
disparities at the ends of the economic spectrum.
Concerns about distributive justice are also difficult to dispense with. Again, it is hard to
see how these concerns will prevent the use of pharmacological enhancements. In the US,
wide disparities in access to and quality of health care and education are tolerated.
Pharmacological enhancement may not be so different from these other "life enhancers".
The autonomy concern is directed at the possibility that what starts out as a matter of
choice ends up as a coercive force. These coercive forces may be explicit or implicit.
Explicit coercion might be seen with classes of individuals who might be expected to take
certain medications for the greater good. Such precedents exist in the military,45 and they

may seep into other specialised professions. One study found that commercial pilots
taking a cholinesterase inhibitor performed better in emergency situations on simulation
experiments than did pilots taking placebos.20 If these results were robust and reliable
could pilots be encouraged through financial incentives to take these? Could they be
required to take such medications? Could individuals with medical contra-indications to
these medications be banned from the profession?
The implicit coercive pressures are more complicated, and, in some sectors of society,
they are likely to be quite forceful. In winner take all environments, slight incremental
advantages have disproportionate consequences.46 This point is made most clearly in
sports. Thus, the difference between being first or fourth in the 100 meters at the
Olympics is huge, even though objectively both athletes are indistinguishable when
compared to the population at large. Similar pressures apply to athletes in other
professional sports, such as baseball or football. The pressure to take advantage of slight
improvements is sufficient to have athletes risk significant side effects of medications as
well as public sanctions for their behaviour. Also, many athletes are willing to engage in
pharmacological enhancements in an environment in which "fairness" is explicitly
valued. Many business and professional environments are set up to make the most of
competition. It is not unusual for professionals to work 80 or 90 hours a week, while their
children enrol in several sports programmes and after school music programmes to ensure
they can make competitive applications to colleges. The pressures for such children to
take stimulant drugs to help with academic performance are already evident. The worry is
that we may encounter the "Red Queen" principle.47i
When Alice in Wonderland finally catches up with the Red Queen she finds that they are
both running hard, but not moving forward. The Red Queen points out to Alice that
sometimes one needs to run as fast as possible, just to stay in place. In some sectors of our
society one might need to make use of every possible advantage including enhancements,
just to stay in place.
In my view, the practice of cosmetic neurology is inevitable. This claim is predictive, not
prescriptive.48 While the ethical concerns are real and run deep, the countervailing social
pressures seem overwhelming. Pharmaceutical companies have significant economic
incentives to expand their markets to healthy individuals. Since 1997, the Food and Drug
Administration has allowed direct advertising to consumers. Television advertisements
now give permission to indulge in a pepperoni pizza without the fear of heartburn because
one could take an H2 blocker prophylactically. One would be surprised if similar
advertisements did not recommend getting an edge with cognitive enhancers or a boost
with mood manipulators.
While the coming of cosmetic neurology is in my view inevitable, the specific shape it
will take may vary in different locations—for example, winner take all pressures vary in
different cultures and within different sectors of society. The ways that these promises
and predicaments will settle into practice is likely to be reflective of cultural norms.
Education is an example of an enhancer that is potentially available to everybody and has
a huge impact on social wellbeing. Perhaps current disparities in availability and quality

of education in different countries may predict future norms of access to pharmacological
enhancements.

A (HYPOTHETICAL) CLINICAL SCENARIO
My clinical practice of neurology has changed. Having struggled through a classic winner
take all environment, the world of National Institutes of Health (NIH) research funding, I
have given up my career as a physician/scientist. In the last few years, NIH funding rates
dropped by half of what they were in an already extremely competitive environment.
Grant awards are based on increasingly slight and probably unreliable differences in
judgments about the merits of an application. These small differences have
disproportionate impacts on peoples’ careers. Encouraged by my original patient, I open a
cosmetic neurology clinic on elegant Rittenhouse Square in Philadelphia. My patient, who
has invested in this clinic, is a great advocate. Largely fuelled by word of mouth, I soon
have a busy and lucrative practice. The patients are wealthy and for the most part grateful.
They sign all the necessary waivers, understand that no specific effects are guaranteed,
and the medications are being used in ways not specifically approved by the Food and
Drug Administration. I no longer bother with bureaucratic burdens imposed by insurance
companies. Things go so well, that we open another clinic on Madison Avenue in New
York. This clinic is also enormously successful. We are now negotiating to open a clinic
in London, with a further eye to Paris and Milan. I am invited frequently to give talks at
corporations. Motivational speakers routinely include a discussion of pharmacological
enhancements in their exhortations. A few other brain spas are opening, but this simply
increases the demand for services at my clinics. I work harder to keep ahead.

CONCLUSION
My intentions in this paper are threefold. Firstly, I have tried to make the case that
advances in cognitive neuroscience and neuropharmacology make cosmetic neurology
plausible and in some form inevitable. The issue is not isolated to doping athletes or
pharmacologically insomniac students. These examples are simply the nose of a camel
that is well on its way into the tent.
Secondly, I have tried to emphasise that the ethical issues that arise, particularly those
centred on character, coercion, and justice are extremely difficult. My own views on these
issues are not settled. I think it makes little sense to have a singular opinion about the
prospect of cosmetic neurology. Each possibility would need to be considered on its own
merits. Particularly tricky are situations in which individuals’ desires to engage or not to
engage in enhancements are at odds with societal desires.
Thirdly, I expect that the practice of cosmetic neurology will challenge conventional
notions of the role of physicians. In the last century plastic surgery struggled with its
identity as demand for services shifted from reconstructive to cosmetic procedures.49 In
the coming century, clinical neurosciences are likely to struggle similarly. The challenge
for physicians will be sorting out their relationships with individuals as patients and
consumers, especially when fiduciary and commercial interests collide.
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FOOTNOTES
i

Evolutionary biologists use the Red Queen principle to describe pressures for survival
among co-evolving species.

REFERENCES
1. Groopman J. Eyes wide open. The New Yorker 2001;3:52–7.
2. Anon. The ethics of brain science. Open your mind. The Economist 2002
May:77–9.
3. Plotz D. The ethics of enhancement. Slate 2003 Mar12.
www.politics.slate.msn.com/id/2079310/ (accessed 18 Aug 2005).
4. Bailey R. The battle for your brain. Reason online 2003 Feb.
www.reason.com/0302/fe.rb.the.shtml (accessed 18 Aug 2005).
5. Begley S. Memory drugs create new ethical minefield. Wall Street Journal 2004
Oct: B1.
6. Fallik D. Improve my mind, please. Philadelphia Inquirer 2005 Mar: D1.
7. Whitehouse P, Juengst E, Mehlman M, et al.Enhancing cognition in the
intellectually intact. Hastings Cent Rep 1997;27:14–22.[Medline]
8. Marcus S. Neuroethics: mapping the field. New York: Dana Press, 2002.
9. Wolpe P. Treatment, enhancement, and the ethics of neurotherapeutics. Brain
Cogn 2002;50:387–95.[CrossRef][Medline]
10. Farah MJ. Emerging ethical issues in neuroscience. Nat Neurosci 2002;5:1123–
9.[CrossRef][Medline]
11. Chatterjee A. Cosmetic neurology: the controversy over enhancing movement,
mentation and mood. Neurology 2004;63:968–74.[Abstract/Free Full Text]

12. Varlet-Marie E, Gaudard A, Audran M, et al.
Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in
doping control. Sports Med 2003;33:301–15.[Medline]
13. Gaudard A, Varlet-Marie E, Bressolle F, et al.Drugs for increasing oxygen
transport and their potential use in doping. Sports Med 2003;33:187–
212.[Medline]
14. Heath T. Senate warns baseball on steroids testing. Washington Post 2004 Mar:
A01.
15. Rudman D, Feller A, Nagraj H, et al. Effects of human growth hormone in men
over 60 years old. N Engl J Med 1990;323:1–6.[Abstract/Free Full Text]
16. Barton-Davis E, Shoturma D, Musaro A, et al.Viral mediated expression of
insulin-like growth factor I blocks the aging-related loss of skeletal muscle
function. Proc Natl Acad Sci 1998;95:15603–7.[Abstract/Free Full Text]
17. Tindall B. Better playing through chemistry. New York Times 17 2004 Oct.
www.query.nytimes.com/gst/health/articlepage.html?res=940DE7DC1E3BF934A25753C1A9629C8B63 (accessed 18 Aug
2005).
18. Walker-Batson D, Smith P, Curtis S, et al.Amphetamine paired with physical
therapy accelerates motor recovery after stroke: further evidence. Stroke
1995;26:2254–9.[Abstract/Free Full Text]
19. Grade C, Redford B, Chrostowski J, et al.Methylphenidate in early poststroke
recovery: a double-blind, placebo-controlled stud. Arch Phys Med Rehabil
1998;79:1047–50.[CrossRef][Medline]
20. Yesavage J, Mumenthaler M, Taylor J, et al.Donezepil and flight simulator
performance: effects on retention of complex skills. Neurology 2001;59:123–5.
21. Turner D, Robbins T, Clark L, et al. Cognitive enhancing effects of modafinil in
healthy volunteers. Psychopharmacology 2003;165:260–9.[Medline]
22. Caldwell JJ, Caldwell J, Smythe NR, et al.A double -blind, placebo-controlled
investigation of the efficacy of modafinil for sustaining the alertness and
performance of aviators: a helicopter simulator study. Psychopharmacology
2000;150:272–82.[CrossRef][Medline]
23. Babcock Q, Byrne T. Student perceptions of methylphenidate abuse at a public
liberal arts college. J Am Coll Health 2000;49:143–5.[Medline]

24. Mattay V, Goldberg T, FF. et al Catechol O-methyltransferase val158-met
genotype and individual variation in the brain response to amphetamine. Proc
Natl Acad Sci 2003;100:6186–91.[Abstract/Free Full Text]
25. Lynch G. Memory enhancement: the search for mechanism-based drugs. Nat
Neurosci Suppl 2003;5:1035–8.
26. Ingvar M, Ambros-Ingerson J, Davis M, et al.Enhancement by an ampakine of
memory encoding in humans. Expl Neurol 1997;146:553–9.[CrossRef]
27. Tully T, Bourtchouladze R, Scott R, et al.Targeting the CREB pathway for
memory enhancers. Nat Rev Drug Discov 2003;2:267–77.[CrossRef][Medline]
28. Scott R, Bourtchouladze R, Gossweiler S, et al.CREB and the discovery of
cognitive enhancers. J Mol Neurosci 2002;19:171–7.[Medline]
29. The National Institute of Mental Health. The numbers count: mental disorders
in America. Washington, DC: NIH Publication, 2003, No 01-4584.
30. Kessler R, Chui W, Demler O, et al.Prevalence, severity, and comorbidity of 12 month DSM IV disorders in the National Comorbidity Survey Replication. Arch
Gen Psychiatry 2005;62:617–27.[Abstract/Free Full Text]
31. Pitman R, Sanders K, Zusman R, et al. Pilot study of secondary prevention of
post-traumatic stress disorder with propanolol. Biol Psychiatry 2002;51:189–
92.[CrossRef][Medline]
32. Knutson B, Wolkowitz O, Cole S, et al.Selective alteration of personality and
social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373–
9.[Abstract/Free Full Text]
33. Tse WA, Bond. Serotonergic intervention affects both social dominance and
affiliative behavior. Psychopharmacology 2002;161:373–9.
34. Holmes A, Heilig M, Rupniak N, et al. Neuropeptide systems as novel
therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci
2003;24:580–8.[CrossRef][Medline]
35. Walker D, Toufexis D, Davis M. Role of the bed nucleus of the stria terminalis
versus amygdala in fear, stress, and anxiety. Eur J Pharmacol 2003;463:199–
216.[CrossRef][Medline]
36. Davis M. Are different parts of the extended amygdala involved in fear versus
anxiety? Biol Psychiatry 1998;44:1239–47.[CrossRef][Medline]
37. Salzano J. Taming stress. Sci Am 2003;289:87–95.

38. Kosfeld M, Heinrichs M, Zak P, et al. Oxytocin increases trust in humans. Nature
2005;435:673–6.[CrossRef][Medline]
39. Flower R. Lifestyle drugs: pharmacology and the social agenda. Trends
Pharmacol Sci 2004;25:182–5.[CrossRef][Medline]
40. President’s Council on Bioethics. Beyond therapy: biotechnology and the
pursuit of happiness. www.bioethics.gov/reports/beyondtherapy/index.html
(accessed 18 Aug 2005).
41. Singer T, Seymour B, O’Doherty J, et al.Empathy for pain involves the affective
but not sensory components of pain. Science 2004;303:1157–62.[Abstract/Free
Full Text]
42. Avenanti A, Bueti D, Galati G, et al.Transcrania mag netic stimulation highlights
the sensorimotor side of empathy for pain. Nat Neurosci 2005;8:955–
60.[Medline]
43. Caton D. What a blessing she had chloroform: the medical and social response to
the pain of childbirth from 1800 to the present. New Haven, CT: Yale University
Press, 1999.
44. Cusick J. Spirituality and voluntary pain. APS Bulletin 2003.
www.ampainsoc.org/pub/bulletin/sep03/path1.htm (accessed 18 Aug 2005).
45. Russo M, Maher C. Campbell W. Cosmetic neurology: the controversy over
enhancing movement, mentation, and mood [letter]. Neurology 2005;64:1320–
1.[Free Full Text]
46. Frank RH, Cook PJ. The winner-take-all society. New York: The Free Press,
1995.
47. Van Valen L. A new evolutionary law. Evolutionary Theory 1973;1:1–30.
48. Dees R. Slippery slopes, wonder drugs, and cosmetic neurology. Neurology
2004;63:951–2.[Free Full Text]
49. Sullivan DA. Cosmetic surgery. The cutting edge of commercial medicine in
America. New Brunswick, NJ: Rutgers University Press, 2001.

